With this collection, Nature Communications, Nature, Nature Cancer, Nature Neuroscience, Nature Progress Oncology, Nature Progress Brain Health, and ...

Neurotoxicity impacting the central and peripheral nervous systems is a considerable adverse effect of both conventional and novel cancer therapies. In this Review, Karschnia et al. outline what is currently known about the mechanisms that underlie the clinical symptoms of central nervous system injury and peripheral neuropathy and the ongoing development of interventions to treat and prevent this unmet medical need.

This link will take you to a page that’s not on LinkedIn

Purpose This study aimed to reveal the factors affecting the therapeutic response of refractory meningiomas treated with [177Lu]Lu-DOTATATE and to collect initial tumor absorbed doses. Methods Patient...

Abstract. Intense efforts are employed to optimize neurosurgical resection of gliomas in different clinical scenarios. However, the level of evidence emplo

The aim of this retrospective study was to evaluate the correlation between findings from somatostatin receptor (SSTR) PET/CT and histopathology in patients with suspected intracranial meningiomas. Me...

Radiotheranostics represent a cutting-edge advancement in the management of noncommunicable diseases, integrating diagnostic imaging with targeted rad…

Targeted radionuclide therapy (TRT) is a therapeutic modality that combines the strengths of radiotherapy and systemic molecularly targeted therapy. Over the past few years, new TRT agents have been d...

Purpose Amino acid PET with [18F]-fluoroethylthyrosine ([18F]FET-PET) is frequently utilized in gliomas. Most studies on prognostication based on amino acid PET comprise mixed cohorts of brain tumors ...

AbstractBackground. We evaluated the amino acid PET-based response assessment criteria (PET RANO 1.0) for their proficiency in predicting longer survival i

stant tumor manifestation. However, multimodal MRI revealed a benign capillary telangiectasia in the anterior cingulate gyrus. While 18F-FET-PET is highly sensitive for detecting tumor activity, vascu...

AbstractBackground. Early after surgery and completion of first-line radiotherapy with concomitant temozolomide, the prediction of progression-free and ove

Purpose The isocitrate dehydrogenase (IDH) genotype is crucial for diagnosing and managing adult-type diffuse glioma. We investigated spatial tumour characteristics in treatment-naïve glioma using an ...

Vallentgoed et al. integrate clinical and multiomic data from persons with matched initial and recurrent IDH-mutant astrocytomas to identify progression-associated mechanisms and report a DNA methylat...

European Journal of Nuclear Medicine and Molecular Imaging -

Vorasidenib, a dual isocitrate dehydrogenase 1/2 (IDH1/2) inhibitor, showed superior efficacy in prolonging progression-free survival and time to next intervention in IDH-mutant grade 2 gliomas. This...

nt-related changes such as pseudoprogression and pseudoresponse from true tumor relapse in patients receiving immunotherapy or targeted therapies for brain metastases and gliomas, often outperforming ...

Abstract. The Response Assessment in NeuroOncology (RANO) criteria for response to treatment in glioma make a distinction between enhancing and unenhancing